CMA says tribunal “wrong” to overturn pharma fine

The UK’s Competition Appeal Tribunal erred on the test required for the Competition and Markets Authority to fine drugmakers for excessive pricing, the authority’s counsel has argued.


Get unlimited access to all Global Competition Review content